vs
F5, Inc.（FFIV）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
F5, Inc.的季度营收约是Revvity的1.1倍（$811.7M vs $772.1M），F5, Inc.净利率更高（18.2% vs 12.7%，领先5.5%），F5, Inc.同比增速更快（11.0% vs 5.9%），过去两年Revvity的营收复合增速更高（9.0% vs 8.0%）
F5, Inc.是一家美国科技企业，专注于应用安全、多云管理、线上反欺诈、应用交付网络（ADN）相关业务，同时提供应用可用性与性能优化、网络安全、访问授权管理等产品及解决方案，助力各行业客户保障数字化业务稳定运营，提升运行效率。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FFIV vs RVTY — 直观对比
营收规模更大
FFIV
是对方的1.1倍
$772.1M
营收增速更快
FFIV
高出5.2%
5.9%
净利率更高
FFIV
高出5.5%
12.7%
两年增速更快
RVTY
近两年复合增速
8.0%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $811.7M | $772.1M |
| 净利润 | $148.0M | $98.4M |
| 毛利率 | 81.4% | — |
| 营业利润率 | 22.1% | 14.5% |
| 净利率 | 18.2% | 12.7% |
| 营收同比 | 11.0% | 5.9% |
| 净利润同比 | 1.5% | 3.9% |
| 每股收益（稀释后） | $2.58 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FFIVRVTY
| Q1 26 | $811.7M | — | ||
| Q4 25 | $822.5M | $772.1M | ||
| Q3 25 | $810.1M | $698.9M | ||
| Q2 25 | $780.4M | $720.3M | ||
| Q1 25 | $731.1M | $664.8M | ||
| Q4 24 | $766.5M | $729.4M | ||
| Q3 24 | $746.7M | $684.0M | ||
| Q2 24 | $695.5M | $691.7M |
净利润FFIVRVTY
| Q1 26 | $148.0M | — | ||
| Q4 25 | $180.1M | $98.4M | ||
| Q3 25 | $190.5M | $46.7M | ||
| Q2 25 | $189.9M | $53.9M | ||
| Q1 25 | $145.5M | $42.2M | ||
| Q4 24 | $166.4M | $94.6M | ||
| Q3 24 | $165.3M | $94.4M | ||
| Q2 24 | $144.1M | $55.4M |
毛利率FFIVRVTY
| Q1 26 | 81.4% | — | ||
| Q4 25 | 81.5% | — | ||
| Q3 25 | 82.2% | 53.6% | ||
| Q2 25 | 81.0% | 54.5% | ||
| Q1 25 | 80.7% | 56.5% | ||
| Q4 24 | 81.7% | — | ||
| Q3 24 | 80.8% | 56.3% | ||
| Q2 24 | 80.4% | 55.7% |
营业利润率FFIVRVTY
| Q1 26 | 22.1% | — | ||
| Q4 25 | 26.0% | 14.5% | ||
| Q3 25 | 25.4% | 11.7% | ||
| Q2 25 | 25.2% | 12.6% | ||
| Q1 25 | 21.7% | 10.9% | ||
| Q4 24 | 26.8% | 16.3% | ||
| Q3 24 | 25.6% | 14.3% | ||
| Q2 24 | 23.4% | 12.4% |
净利率FFIVRVTY
| Q1 26 | 18.2% | — | ||
| Q4 25 | 21.9% | 12.7% | ||
| Q3 25 | 23.5% | 6.7% | ||
| Q2 25 | 24.3% | 7.5% | ||
| Q1 25 | 19.9% | 6.4% | ||
| Q4 24 | 21.7% | 13.0% | ||
| Q3 24 | 22.1% | 13.8% | ||
| Q2 24 | 20.7% | 8.0% |
每股收益（稀释后）FFIVRVTY
| Q1 26 | $2.58 | — | ||
| Q4 25 | $3.10 | $0.86 | ||
| Q3 25 | $3.25 | $0.40 | ||
| Q2 25 | $3.25 | $0.46 | ||
| Q1 25 | $2.48 | $0.35 | ||
| Q4 24 | $2.82 | $0.77 | ||
| Q3 24 | $2.79 | $0.77 | ||
| Q2 24 | $2.44 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.6B | $7.3B |
| 总资产 | $6.5B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FFIVRVTY
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.2B | $919.9M | ||
| Q3 25 | $1.3B | $931.4M | ||
| Q2 25 | $1.4B | $991.8M | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | $1.1B | $1.2B | ||
| Q2 24 | $935.6M | $2.0B |
股东权益FFIVRVTY
| Q1 26 | $3.6B | — | ||
| Q4 25 | $3.5B | $7.3B | ||
| Q3 25 | $3.6B | $7.4B | ||
| Q2 25 | $3.5B | $7.6B | ||
| Q1 25 | $3.3B | $7.6B | ||
| Q4 24 | $3.2B | $7.7B | ||
| Q3 24 | $3.1B | $7.9B | ||
| Q2 24 | $3.0B | $7.9B |
总资产FFIVRVTY
| Q1 26 | $6.5B | — | ||
| Q4 25 | $6.3B | $12.2B | ||
| Q3 25 | $6.3B | $12.1B | ||
| Q2 25 | $6.1B | $12.4B | ||
| Q1 25 | $5.9B | $12.4B | ||
| Q4 24 | $5.9B | $12.4B | ||
| Q3 24 | $5.6B | $12.8B | ||
| Q2 24 | $5.4B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $525.1M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 3.55× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流FFIVRVTY
| Q1 26 | $525.1M | — | ||
| Q4 25 | $159.2M | $182.0M | ||
| Q3 25 | $208.1M | $138.5M | ||
| Q2 25 | $282.2M | $134.3M | ||
| Q1 25 | $256.6M | $128.2M | ||
| Q4 24 | $202.8M | $174.2M | ||
| Q3 24 | $246.5M | $147.9M | ||
| Q2 24 | $159.0M | $158.6M |
自由现金流FFIVRVTY
| Q1 26 | — | — | ||
| Q4 25 | $149.5M | $161.8M | ||
| Q3 25 | $191.9M | $120.0M | ||
| Q2 25 | $273.7M | $115.5M | ||
| Q1 25 | $246.1M | $112.2M | ||
| Q4 24 | $194.7M | $149.8M | ||
| Q3 24 | $240.4M | $125.6M | ||
| Q2 24 | $153.1M | $136.6M |
自由现金流率FFIVRVTY
| Q1 26 | — | — | ||
| Q4 25 | 18.2% | 21.0% | ||
| Q3 25 | 23.7% | 17.2% | ||
| Q2 25 | 35.1% | 16.0% | ||
| Q1 25 | 33.7% | 16.9% | ||
| Q4 24 | 25.4% | 20.5% | ||
| Q3 24 | 32.2% | 18.4% | ||
| Q2 24 | 22.0% | 19.7% |
资本支出强度FFIVRVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.2% | 2.6% | ||
| Q3 25 | 2.0% | 2.6% | ||
| Q2 25 | 1.1% | 2.6% | ||
| Q1 25 | 1.4% | 2.4% | ||
| Q4 24 | 1.1% | 3.4% | ||
| Q3 24 | 0.8% | 3.3% | ||
| Q2 24 | 0.8% | 3.2% |
现金转化率FFIVRVTY
| Q1 26 | 3.55× | — | ||
| Q4 25 | 0.88× | 1.85× | ||
| Q3 25 | 1.09× | 2.97× | ||
| Q2 25 | 1.49× | 2.49× | ||
| Q1 25 | 1.76× | 3.03× | ||
| Q4 24 | 1.22× | 1.84× | ||
| Q3 24 | 1.49× | 1.57× | ||
| Q2 24 | 1.10× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FFIV
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
